Runs digital audience-targeting and marketing campaigns for pharmaceutical and life sciences brands, reaching healthcare professionals and patients.
10-K for FY2025, filed Mar 12, 2026By combining artificial intelligence (“AI”)-driven tools with our original financial messaging solution, we progressively enhanced our…View ↗
After acquiring Healthy Offers, Inc. (d/b/a “Medicx” or “Medicx Health”) in 2023, we expanded our capabilities to include…View ↗
Our primary media offering is banner messaging delivered to HCPs. Banner messages include brand messaging, therapeutic support messaging…View ↗
Life sciences customers pay for delivered messages and campaign services, with fees per message or redemption, flat fees over time, or a fee when a program is completed; some also buy data subscriptions.
10-K for FY2025, filed Mar 12, 2026
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗$109.4M
10-K for FY2025, filed Mar 12, 2026
$109.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue recognized over time
|
100% |
Revenue recognized over time, FY2025
$109.2M Sources
|
|
|
Revenue recognized at a point in time
Sold outright
|
0.2% |
Revenue recognized at a point in time, FY2025
$215K Sources
|
Sold outright |
Pharmaceutical manufacturers and life sciences brands, plus their agency partners, are the advertiser clients; campaigns reach audiences through publisher partners and EHR and e-prescribing platforms.
10-K for FY2025, filed Mar 12, 2026Our go-to-market strategy for the business aligns sales and marketing efforts while keeping customer engagement at the core. Engaging…View ↗
Our proprietary technology platform enables us to curate privacy safe DTC audiences, dynamic HCP and DTC audiences, and effectively manage…View ↗
Our primary media offering is banner messaging delivered to HCPs. Banner messages include brand messaging, therapeutic support messaging…View ↗
Yes. It kept 5 cents of every revenue dollar as net income in FY2025 and turned 17 cents into free cash flow.
8-K, filed Aug 12, 2026
On August 7, 2026, the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”) approved a finance leadership succession…View ↗
8-K, filed May 12, 2026
-2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 millionView ↗
8-K, filed Mar 30, 2026
On March 24, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of OptimizeRx Corporation (the “Company”) approved…View ↗
Growing. Revenue grew 79% in 4 years, from $61.3M in FY2021 to $109.4M in FY2025, about 16% a year.
Broader consumer marketing
The older report describes point-of-care and healthcare-provider engagement solutions; the latest report adds direct-to-consumer marketing and audience targeting by geography through MNT.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 12, 2026After acquiring Healthy Offers, Inc. (d/b/a “Medicx” or “Medicx Health”) in 2023, we expanded our capabilities to include…View ↗
Dynamic Audience Activation Platform generates dynamic audiences with predictive analytics via machine learning methods. DAAP identifies…View ↗
Our primary media offering is banner messaging delivered to HCPs. Banner messages include brand messaging, therapeutic support messaging…View ↗
Competes with ConnectiveRx
10-K for FY2022, filed Mar 10, 2023Our platforms compete broadly in the highly competitive pharmaceutical and life sciences digital marketing industry that is dominated by…View ↗
Loading...